05) (

Posted on August 9, 2019 by admin

However, the expressions of Proteases inhibitor Hsp90-beta and annexin A1 did not correlate with other clinicopathologic factors such as gender, age, smoking imaging, and pleural invasion. Table 4 Correlation between clinico-pathological features and the expressions of Hsp90-beta and annexin A1 in lung cancer Parameter Group

N Expression of Hsp90-beta Expression of annexin A1 Low (%) Moderate (%) High (%) χ 2value Pvalue Low (%) Moderate (%) High (%) χ 2value Pvalue Gender                           Male 73 12(16.4) 22(30.1) 39(53.4) 4.49 0.105 18(24.7) 26(35.6) 29(39.7) 5.09 0.078   Female 23 2(8.7) 3(13) 18(78.3) 2(8.7) 6(26.1) 15(65.2) Ages                           <60 54 8(14.8) 13(24.1) 33(61.1) 0.251 0.882 8(14.8) 20(37)

26(48.1) 2.798 0.247   ≥60 42 6(14.3) 12(28.6) 24(57.1) 12(28.6) 12(28.6) 18(42.9) Smoking                           0 37 3(8.1) 6(16.2) 28(75.7) 8.28 click here 0.082 5(13.5) 10(27) 22(59.5) 3.856 0.248   0.1–40 12 1(8.33) 5(41.67) 6(50) 2(16.7) 5(41.7) 5(41.7)   >40 47 10(21.3) 14(29.8) 23(48.9) 13(27.7) 17(36.2) 17(36.2) Histology                           LAC 39 8(20.5) 9(23.1) 22(56.4)★ 8.16 <0.05 7(17.9) 9(23.1) 23(59)▴ 7.513 <0.05   LSCC 41 5(12.2) 13(31.7) 23(56.1)★ 10(24.4) CBL0137 mw 19(46.3) 12(29.3)▴   SCLC 11 1(9.1) 1(9.1) 9(81.82)★ 2(18.2) 2(18.2) 7(63.6)▴   Others 5 0(0) 2(40) 3(60) 1(20) 2(40) 2(40) Pathological grade                           Poorly 26 1(3.8) 4(15.4) 21(80.8) 31.26 <0.0005 2(7.7) 2(7.7) 22(84.6) 38.26 <0.0005   Moderately 33 1(3.03) 12(36.36) 20(60.61) 5(15.2) 21(63.6) 7(21.2)   Well 22 11(50) 6(27.3) 5(22.7) 10(45.5) 5(22.7) 7(31.8)   Undifferentiated 15 1(6.67) 3(20) 11(73.33) 3(20) 4(26.7) 8(53.3) Lymphatic invasion        

                  N0 41 12(29.3) 18(43.9) 11(26.8)★★ 31.02 <0.0005 17(41.5) 13(31.7) 11(26.8)▴▴ 19.97 <0.0005   N1 40 1(2.5) 5(12.5) Immune system 34(85) ★★ 2(5.5) 17(34.5) 21(60) ▴▴   N2 11 0(0) 2(18.2) 9(81.8) ★★ 1(9.1) 1(9.1) 9(81.82)▴▴   N3 4 0(0) 0(0) 4(100) ★★ 0(0) 0(0) 4(100) ▴▴ hydrothorax                           Absent 82 13(15.9) 23(28) 46(56.1) 2.51 0.285 18(22) 29(35.4) 35(42.7) 2.25 0.324   Present 14 1(7.1) 2(14.3) 11(78.6) 2(14.3) 3(21.4) 9(64.3) T stage                           T1 – T2 57 11(19.3) 22(38.6) 24(42.1) 14.72 0.001 17(29.8) 23(40.4) 17(29.8) 14.83 0.001   T3 – T4 28 2(7.1) 2(7.1) 24(85.7) 1(3.6) 7(25) 20(71.4)   Unavailable 11 1(9.1) 1(9.1) 9(81.82) 2(18.18) 2(18.18) 7(63.64) pTNM                           IB 3 1(33.3) 2(66.7) 0(0)● 11.449 0.022 0(0) 3(100) 0(0)●● 9.97 0.008   IIA-IIB 53 10(18.9) 19(35.8) 24(45.3)● 16(30.2) 20(37.7) 17(32.1)●●   IIIA-IIIB 25 2(8) 3(12) 20(82)● 2(8) 6(24) 17(68)●●   IV 4 0(0) 0(0) 4(100)● 0(0) 1(25) 3(75)●●   Unavailable 11 1(9.1) 1(9.1) 9(81.82) 2(18.18) 2(18.18) 7(63.64) Imaging                           Central 43 5(11.63) 15(34.88) 23(53.49) 2.68 0.261 11(20.9) 16(41.9) 16(37.2) 2.07 0.356   Ambient 49 9(18.37) 10(24.49) 30(57.14) 8(20.4) 16(32.7) 25(46.

Related posts:

1. BC3 and BCBL-1 have wild-type practical p53 and were additional s
2. Variations in survival amongst patients with a low versus high le
3. Secondly, multivariable models estimated the independent associat
4. sakei regulated by σLsa H, the experimental system described abov
5. Cervical cancer can arise from cells containing exclusively episo

This entry was posted in Antibody. Bookmark the permalink.